ConductScience.org, home

Paper39450552

Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).

Hao W and 6 others. Int J Mol Med, 2025. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). Papers, record 39450552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39450552

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
PubMed
Journal
Int J Mol Med
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
2.39, provisional
iCite
Revised in PubMed
2024-11-07
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hao WWenhui
2Rajendran BKBarani Kumar
3Cui TTingting
4Sun JJiayi
5Zhao YYingchun
6Palaniyandi TThirunavukkarasu
7Selvam MMasilamani

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Precision MedicineMajor topic
MutationMajor topic
Humans
Female
Biomarkers, Tumor
Molecular Targeted Therapy

Source PubMed

Download CSV of topics

References141

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131756919Immunotherapy: A Challenge of Breast Cancer Treatment.Cancers (Basel)2019https://conductscience.org/library/papers/31756919PubMed
222862954First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.J Transl Med2012https://conductscience.org/library/papers/22862954PubMed
312960733Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.Anticancer Drugs2003https://conductscience.org/library/papers/12960733PubMed
422068656A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.Clin Cancer Res2011https://conductscience.org/library/papers/22068656PubMed
529236940Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.Ann Oncol2018https://conductscience.org/library/papers/29236940PubMed
638244459"Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer."Breast2024https://conductscience.org/library/papers/38244459PubMed
738193640Mutational profiling of mitochondrial DNA reveals an epithelial ovarian cancer-specific evolutionary pattern contributing to high oxidative metabolism.Clin Transl Med2024https://conductscience.org/library/papers/38193640PubMed
811839652Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial.Clin Cancer Res2002https://conductscience.org/library/papers/11839652PubMed
923819870Identifying Mendelian disease genes with the variant effect scoring tool.BMC Genomics2013https://conductscience.org/library/papers/23819870PubMed
1019244125Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.Cancer Res2009https://conductscience.org/library/papers/19244125PubMed
1133893808MutationTaster2021.Nucleic Acids Res2021https://conductscience.org/library/papers/33893808PubMed
1234507558Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment.World J Surg Oncol2021https://conductscience.org/library/papers/34507558PubMed
1328274957An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.Cancer Discov2017https://conductscience.org/library/papers/28274957PubMed
143821953[A different form for the certification of cause of death].Ned Tijdschr Geneeskd1986https://conductscience.org/library/papers/3821953PubMed
1528650338IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017https://conductscience.org/library/papers/28650338PubMed
1630546008Immune checkpoint inhibitors: recent progress and potential biomarkers.Exp Mol Med2018https://conductscience.org/library/papers/30546008PubMed
1722130160A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.J Immunother2012https://conductscience.org/library/papers/22130160PubMed
1837239898Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.Int J Mol Sci2023https://conductscience.org/library/papers/37239898PubMed
1923801303Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.Invest New Drugs2013https://conductscience.org/library/papers/23801303PubMed
2030674894Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.Nat Commun2019https://conductscience.org/library/papers/30674894PubMed

See all 141 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42649570
Integrated RNA Sequencing and Multi-Bioinformatics Analyses Reveal the Molecular Mechanisms Underlying the Anti-Breast Cancer Effects of the Fritillariae Thunbergii Bulbus-Bolbostemmatis Rhizoma Herb Pair.
Cell Biochem Funct2026https://conductscience.org/library/papers/42649570PubMed
42265489Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.Discov Oncol2026https://conductscience.org/library/papers/42265489PubMed
41979751Mean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy.Discov Oncol2026https://conductscience.org/library/papers/41979751PubMed
41764124Crosstalk between mitophagy and breast cancer: mechanisms of action and clinical applications.J Cancer Res Clin Oncol2026https://conductscience.org/library/papers/41764124PubMed
40407592Building a Hand-Curated ceRNET for Endometrial Cancer, Striving for Clinical as Well as Medicolegal Soundness: A Systematic Review.Noncoding RNA2025https://conductscience.org/library/papers/40407592PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39450552

GET https://conductscience.org/api/papers/v1/39450552/references?page=2